Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
World-first lung cancer vaccine trials started in seven countries
The lung cancer vaccine clinical trial had been recently launched in seven countries, including the United States, Japan, and Spain, which could prove to be...
Lazertinib with amivantamab-vmjw is approved by the USFDA for non-small lung cancer
August 2024: The Food and Drug Administration (FDA) has granted approval for the use of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant,...
Neoadjuvant/adjuvant durvalumab is approved by the USFDA for resectable non-small cell lung cancer
The USFDA approved neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable NSCLC. It marked a turning point in cancer treatment by opening up new...
The FDA has granted approval for the use of vorasidenib in the treatment of Grade 2 astrocytoma or oligodendroglioma in patients having a specific IDH1 or IDH2 mutation
The FDA has granted approval for the use of vorasidenib in treating Grade 2 astrocytoma or oligodendroglioma in patients with a specific IDH1 or IDH2...
The FDA has granted accelerated approval to afamitresgene autoleucel for the treatment of unresectable or metastatic synovial sarcoma
The FDA has granted accelerated approval to afamitresgene autoleucel, a CAR T-cell therapy, for the treatment of unresectable or metastatic synovial sarcoma in patients with...
The FDA has broadened the indication for dostarlimab-gxly to include the treatment of endometrial cancer in combination with chemotherapy
Dostarlimab-gxly is now indicated for the treatment of endometrial cancer in association with chemotherapy. The broader indication provides that it will be used as first-line...
The FDA has granted approval for the use of daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of multiple myeloma
The FDA has granted approval for the utilization of daratumumab and hyaluronidase-fihj in conjunction with bortezomib, lenalidomide, and dexamethasone as a treatment for multiple myeloma....
The FDA has granted expedited approval to epcoritamab-bysp for the treatment of R/R follicular lymphoma
Epcoritamab-bysp has received accelerated approval from the FDA for the treatment of relapsed or refractory (R/R) follicular lymphoma, a subtype of non-Hodgkin lymphoma. Epcoritamab-bysp is...
CAR T Cell Therapy for Blood Cancers
CAR T-cell therapy represents a new frontier of treatment against blood cancers, like leukemia and lymphoma. In this brand-new treatment, the T-cells are isolated in...
The FDA Approved The First Engineered T Cell Therapy for Solid Tumors
The FDA just approved the first engineered T cell therapy for solid tumors, signaling a significant advancement in cancer treatment. This new therapy uses genetically...
CAR T Cell Therapy for Relapsed and Refractory Cancers
It is also an innovative treatment for the relapsed or refractory cancers. Treatment involves genetic modification of a patient's T cells to express chimeric antigen...
CAR T Cell Therapy for Pediatric Cancer
Introduction Although relatively rare, pediatric malignancy is one of the leading causes of mortality in children worldwide. Even though traditional therapies like chemotherapy, radiation, and...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.